Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma
Sign Up to like & getrecommendations! Published in 2022 at "Translational Oncology"
DOI: 10.1016/j.tranon.2022.101368
Abstract: Highlights • A novel pair of orthotopic PDX models of glioma bearing IDH1-R132H/R132C mutations.• New mutant IDH1i (SY-435) with standard therapy led to strong therapeutic efficacy.• H3K4/K9 methylation/mtDNA-encoded molecules mediate anti-tumor activity of SYC-435.• Discovered… read more here.
Keywords: 435 standard; syc 435; models glioma; standard therapy ... See more keywords